In PepBank now:147 peptides, 6 blends and 13 other compounds97,577 study results from 17,383 studies8,473 clinical trialsUpdated
Comparing 2 peptides · Data version 308560
Swipe sideways to see every peptide.
| Peptide | Synthetic analog Melanotan I (afamelanotide) | Synthetic analog Melanotan II | |
|---|---|---|---|
| Identity | |||
| Kind | Synthetic analog | Synthetic analog | |
| Area | Sexual health and hormones | Sexual health and hormones | |
| Evidence | |||
| Amount of evidence | 667 | 914 | |
| Evidence level | Has results from studies in people | Has results from studies in people | |
| Safety | |||
| Safety results | 36 (29 in people) | 39 (31 in people) | |
| Status | |||
| Approval | |||
| Sport (WADA) | |||
| Registered trials | 23 · 1 active | 1 · 1 active | |
Shared outcomes
From the regulatory data of each peptide.
Outcome groups with study results for at least two of these peptides. Counts include only results from studies that gave the peptide. Bar length is the number of results, on one scale. The bars show how much was studied, not how large an effect was. A peptide with more studies can look stronger here without being stronger. For results, see the randomized results above.
| Outcome group | Melanotan I (afamelanotide) | Melanotan II |
|---|---|---|
| Receptor activity and mechanismSkin and wound | 231521781 | 160 |
PepBank is a research reference. Talk to a doctor before you use any peptide.
The EMA label for Scenesse says: “Prevention of phototoxicity in adult patients with erythropoietic protoporphyria (EPP)”
Its most advanced trial is in phase 2. The FDA, the EMA and the other sources we use show no approval (as of 9 Oct 2026).
| Appetite and food intakeNervous system and cognition | 2525 | 21912162 |
|---|
| Adverse eventsWhole body | 29245 | 24195 |
|---|
| PigmentationSkin and wound | 4324316 | 761 |
|---|
| Skin and hairSkin and wound | 27252 | 11 |
|---|
| Body weightMetabolic and weight | 33 | 8686 |
|---|
| Inflammation markersRespiratory | 534310 | 29218 |
|---|
| NeuroprotectionNervous system and cognition | 5423418 | 1111 |
|---|
| Immune responseKidney and urinary | 2631112 | 431 |
|---|
| Glycemic controlEndocrine and hormones | 11 | 3535 |
|---|
| PharmacokineticsPharmacology | 10631 | 66 |
|---|
| Liver fat and liver functionLiver | 55 | 981 |
|---|
Each analog against its native parent, residue by residue. Substitutions, non-standard residues and modifications are marked. Calculated from the two sequences.
Melanotan I (afamelanotide) differs from Alpha-melanocyte-stimulating hormone (alpha-MSH) at 2 positions and carries 2 added groups.
What is different
Melanotan II differs from Alpha-melanocyte-stimulating hormone (alpha-MSH) at 4 positions.
What is different
For each outcome that two or more peptides have results for: the best result of a single randomized trial, on the same measure (the same kind of number, the same unit). When a trial has several dose arms, the cell shows the highest dose arm. The trials differ in people, length and dose, so a gap between two cells is not proof that one peptide works better.
No outcome has a randomized-trial result on the same measure for two or more of these peptides yet.
Registered trials, ranked by phase (late phases first), then posted results and enrollment. Status is the registry status. Study results come from published studies. Results posted at ClinicalTrials.gov are shown on each trial page.
Top 3 of 23 trials, ranked by phase, then posted results and enrollment: 3 completed · 3 with posted results · source ClinicalTrials.gov (opens in a new tab)
Clinuvel Pharmaceuticals Limited100 participantsMay 2007 to 9 Dec 2009
Erythropoietic Protoporphyria
Clinuvel Pharmaceuticals Limited93 participantsMay 2012 to Jul 2013
Erythropoietic Protoporphyria
Clinuvel Pharmaceuticals Limited74 participantsSept 2009 to May 2011
Erythropoietic Protoporphyria
1 trial · 1 ongoing · source ClinicalTrials.gov (opens in a new tab)
Hudson Biotech60 participants2 Feb 2026 to est. 17 Feb 2028
NonSegmental Vitiligo · Nonsegmental Vitiligo (Stable)